Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -195.32 Million CNY | -525.12% |
| 2022 | 45.94 Million CNY | 105.81% |
| 2021 | -791.2 Million CNY | -511.43% |
| 2020 | 192.3 Million CNY | 19.05% |
| 2019 | 161.53 Million CNY | -25.42% |
| 2018 | 216.57 Million CNY | -58.55% |
| 2017 | 522.45 Million CNY | -34.32% |
| 2016 | 795.4 Million CNY | 35.11% |
| 2015 | 588.71 Million CNY | 104.21% |
| 2014 | 288.28 Million CNY | 49.43% |
| 2013 | 192.92 Million CNY | 27.01% |
| 2012 | 151.9 Million CNY | 28.94% |
| 2011 | 117.81 Million CNY | 77.26% |
| 2010 | 66.46 Million CNY | 192.14% |
| 2009 | 22.75 Million CNY | 109.8% |
| 2008 | 10.84 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -31.76 Million CNY | -1034.7% |
| 2024 Q1 | 2.9 Million CNY | 101.23% |
| 2024 Q2 | 3.39 Million CNY | 17.14% |
| 2023 Q2 | 25.87 Million CNY | -0.79% |
| 2023 Q1 | 26.07 Million CNY | 176.11% |
| 2023 Q3 | -11.87 Million CNY | -145.91% |
| 2023 Q4 | -235.39 Million CNY | -1882.01% |
| 2023 FY | -195.32 Million CNY | -525.12% |
| 2022 Q3 | 6.22 Million CNY | -17.6% |
| 2022 Q1 | 22.53 Million CNY | 102.38% |
| 2022 FY | 45.94 Million CNY | 105.81% |
| 2022 Q4 | 9.44 Million CNY | 51.74% |
| 2022 Q2 | 7.55 Million CNY | -66.47% |
| 2021 FY | -791.2 Million CNY | -511.43% |
| 2021 Q4 | -947.68 Million CNY | -1881.53% |
| 2021 Q2 | 50.25 Million CNY | -5.23% |
| 2021 Q3 | 53.19 Million CNY | 5.84% |
| 2021 Q1 | 53.02 Million CNY | 154.6% |
| 2020 FY | 192.3 Million CNY | 19.05% |
| 2020 Q1 | 23.69 Million CNY | 544.18% |
| 2020 Q2 | 42.46 Million CNY | 79.24% |
| 2020 Q3 | 115.24 Million CNY | 171.4% |
| 2020 Q4 | 20.82 Million CNY | -81.93% |
| 2019 Q3 | 36.43 Million CNY | -19.05% |
| 2019 Q4 | -5.33 Million CNY | -114.64% |
| 2019 Q2 | 45.01 Million CNY | -47.3% |
| 2019 Q1 | 85.41 Million CNY | 205.21% |
| 2019 FY | 161.53 Million CNY | -25.42% |
| 2018 Q2 | 118.15 Million CNY | 14.4% |
| 2018 Q4 | -81.18 Million CNY | -206.37% |
| 2018 FY | 216.57 Million CNY | -58.55% |
| 2018 Q1 | 103.28 Million CNY | 419.09% |
| 2018 Q3 | 76.32 Million CNY | -35.4% |
| 2017 Q2 | 203.53 Million CNY | -7.12% |
| 2017 FY | 522.45 Million CNY | -34.32% |
| 2017 Q3 | 132.15 Million CNY | -35.07% |
| 2017 Q4 | -32.36 Million CNY | -124.49% |
| 2017 Q1 | 219.13 Million CNY | 200.82% |
| 2016 FY | 795.4 Million CNY | 35.11% |
| 2016 Q3 | 195.49 Million CNY | -45.54% |
| 2016 Q2 | 358.96 Million CNY | 113.54% |
| 2016 Q4 | 72.84 Million CNY | -62.74% |
| 2016 Q1 | 168.09 Million CNY | 3.72% |
| 2015 Q1 | 90.13 Million CNY | -0.55% |
| 2015 Q4 | 162.07 Million CNY | 14.37% |
| 2015 Q3 | 141.71 Million CNY | -27.25% |
| 2015 Q2 | 194.79 Million CNY | 116.11% |
| 2015 FY | 588.71 Million CNY | 104.21% |
| 2014 Q2 | 80.51 Million CNY | 37.2% |
| 2014 Q3 | 58.44 Million CNY | -27.42% |
| 2014 Q4 | 90.63 Million CNY | 55.09% |
| 2014 FY | 288.28 Million CNY | 49.43% |
| 2014 Q1 | 58.68 Million CNY | -12.7% |
| 2013 Q2 | 46.88 Million CNY | 40.75% |
| 2013 Q3 | 45.5 Million CNY | -2.96% |
| 2013 Q4 | 67.22 Million CNY | 47.75% |
| 2013 FY | 192.92 Million CNY | 27.01% |
| 2013 Q1 | 33.31 Million CNY | -0.57% |
| 2012 Q3 | 34.39 Million CNY | -28.81% |
| 2012 Q2 | 48.32 Million CNY | 35.43% |
| 2012 FY | 151.9 Million CNY | 28.94% |
| 2012 Q1 | 35.68 Million CNY | 16.59% |
| 2012 Q4 | 33.5 Million CNY | -2.61% |
| 2011 Q1 | 18.48 Million CNY | -43.14% |
| 2011 Q2 | 41.88 Million CNY | 126.52% |
| 2011 Q4 | 30.6 Million CNY | 14.05% |
| 2011 Q3 | 26.83 Million CNY | -35.93% |
| 2011 FY | 117.81 Million CNY | 77.26% |
| 2010 FY | 66.46 Million CNY | 192.14% |
| 2010 Q4 | 32.51 Million CNY | 104.94% |
| 2010 Q3 | 15.86 Million CNY | 0.0% |
| 2009 FY | 22.75 Million CNY | 109.8% |
| 2008 FY | 10.84 Million CNY | 0.0% |